A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer medicines, can still treat the cancer effectively while causing fewer side effects, especially those affecting the eyes. The study will also look at how well the treatment works overall and how safe it is when administered to the participants.

Trial Details

NCT ID
NCT07227311
Phase
PHASE2
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Belantamab mafodotin
  • Dexamethasone
  • Pomalidomide
  • Bortezomib
  • Carfilzomib
Locations (sample)
  • Los Alamitos, California, United States|33.80307,-118.07256
  • Torrance, California, United States|33.83585,-118.34063
  • Whittier, California, United States|33.97918,-118.03284
  • Fort Myers, Florida, United States|26.62168,-81.84059
  • Macon, Georgia, United States|32.84069,-83.6324

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Applicable to All Arms - BPd, BVd, BKd:
  • Male or female, 18 years or older (at the time consent is obtained).
  • Have a confirmed diagnosis of Multiple Myeloma (MM) as defined by the International Myeloma Working Group (IMWG) criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →